A Phase 3 interventional study of Dulaglutide and Insulin glargine in Type 2 Diabetes and Chronic Kidney Disease, sponsored by Eli Lilly and Company. Completed at 89 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-19.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 15th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 23rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 577 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 50th largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2012, is one of 85 in phase 3, and was the 86th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Insulin glargine was administered subcutaneously (SC) at bedtime per a modified forced-titration treat-to-target algorithm. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
Drug: Insulin glargine · Drug: Insulin lispro
0.75 milligram (mg) of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
Drug: Dulaglutide · Drug: Insulin lispro
1.5 mg of dulaglutide was administered once weekly as a SC injection. Participants were instructed to administer their titrated prandial insulin lispro dose SC with the three most significant meals of the day.
Drug: Dulaglutide · Drug: Insulin lispro
Administered SC
Also known as: LY2189265
Administered SC
Administered SC
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means in HbA1c were calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, macroalbuminuria (MA) region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
Time frame: Baseline, 26 Weeks
Percentage of Participants Whose HbA1c Was <7.0%
Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).
Time frame: 26 Weeks
Percentage of Participants Whose HbA1c Was <8.0%
Percentage of Participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).
Time frame: 26 Weeks
Change From Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG)
The daily mean of 8-point SMPG profile at Week 26 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).
Time frame: Baseline, 26 Weeks
Change From Baseline in Fasting Glucose (FG)
LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured
Time frame: Baseline, 26 Weeks
Change From Baseline in Mean Daily Insulin Lispro Dose
The mean daily insulin was based on a 4-week interval prior to week 26 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
Time frame: Baseline, 26 Weeks
Percentage of Participants With Estimated Average Glucose <154 mg/dL
Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).
Time frame: 26 Weeks
Change From Baseline in Serum Creatinine (sCr)
Change from baseline in serum creatinine (sCr) levels after treatment.
Time frame: Baseline, 26 Weeks
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
The change in estimated glomerular filtration rate (eGFR) by using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
Time frame: Baseline, 26 Weeks
Change From Baseline in Estimated Creatinine Clearance (eCrCl)
Estimated creatinine clearance (eCrCl) was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.
Time frame: Baseline, 26 Weeks
Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR)
The change from baseline in Urinary Albumin to Creatinine Ratio (UACR).
Time frame: Baseline, 26 Weeks
Change From Baseline in Body Weight
LS means were calculated from a REML based MMRM model: Change from Baseline = treatment, week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured. •
Time frame: Baseline, 26 Weeks
Percentage of Participants With Self-Reported Hypoglycemic Events (HE)
Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline through 26 Weeks
Rate of Hypoglycemic Events
Hypoglycemic events (HE) were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline through 26 Weeks
Change From Baseline in HbA1c
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means in HbA1c were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, MA region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
Time frame: Baseline, 52 Weeks
Percentage of Participants Whose HbA1c is <7.0%
Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).
Time frame: 52 Weeks
Percentage of Participants Whose HbA1c is <8.0%
Percentage of participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).
Time frame: 52 Weeks
Change From Baseline in 8-Point SMPG
The daily mean of 8-point SMPG profile at Week 52 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).
Time frame: Baseline, 52 Weeks
Change From Baseline in FG
LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured
Time frame: Baseline, 52 Weeks
Change in Mean Daily Insulin Lispro Dose
The mean daily insulin was based on a 4-week interval prior to week 52 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
Time frame: Baseline, 52 Weeks
Percentage of Participants With Estimated Average Glucose <154 mg/dL
Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).
Time frame: 52 Weeks
Change From Baseline in sCr
Change from baseline in sCr levels after treatment.
Time frame: Baseline, 52 Weeks
Change From Baseline in eGFR
The change in eGFR by using CKD-EPI equation.
Time frame: Baseline, 52 Weeks
Change From Baseline in eCrCl
eCrCl was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.
Time frame: Baseline, 52 Weeks
Change From Baseline in UACR
The change from baseline in UACR
Time frame: Baseline, 52 Weeks
Change From Baseline in Body Weight
LS means were calculated from a REML based MMRM model: Change from Baseline = treatment , week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured.
Time frame: Baseline, 52 Weeks
Percentage of Participants With Self-Reported Hypoglycemic Events (HE)
Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline through 52 Weeks
Rate of Hypoglycemic Events (HE)
HE were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline through 52 Weeks
Participants With Events of Allergic/Hypersensitivity Reactions
Participants with Events of Allergic/Hypersensitivity Reactions: Angioedema Standardized MedDRA Query (SMQ), Anaphylactic Reaction SMQ, or Severe Cutaneous Adverse Reactions SMQ
Time frame: Baseline through 52 Weeks
| Milestone | Insulin Glargine | 0.75 mg Dulaglutide | 1.5 mg Dulaglutide |
|---|---|---|---|
| Started | 194 | 190 | 193 |
| Received at least one dose of study drug | 194 | 190 | 192 |
| Modified intent to treat population | 186 | 180 | 183 |
| Completed | 163 | 160 | 157 |
| Not completed | 31 | 30 | 36 |
| Withdrew: Adverse event | 5 | 2 | 8 |
| Withdrew: Death | 6 | 7 | 2 |
| Withdrew: Lost to follow-up | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 14 | 17 | 18 |
| Withdrew: Physician decision | 5 | 2 | 7 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means in HbA1c were calculated using a restricted maximum likelihood (REML) based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, macroalbuminuria (MA) region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
| percentage of HbA1c | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -1.13 ± 0.12 | -1.12 ± 0.12 | -1.19 ± 0.13 |
Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Percentage of Participants Whose HbA1c Was <7.0% | 34.6 | 31.7 | 37.5 |
Percentage of Participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Percentage of Participants Whose HbA1c Was <8.0% | 75.3 | 72.6 | 78.3 |
The daily mean of 8-point SMPG profile at Week 26 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).
| milligrams/deciliter (mg/dL) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in 8-Point Self-Monitored Plasma Glucose (SMPG) | -37.6 ± 3.41 | -31.7 ± 3.53 | -33.7 ± 3.77 |
LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured
| milligram/deciliter (mg/dL) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Fasting Glucose (FG) | -19.1 ± 6.00 | 17.7 ± 6.14 | 23.1 ± 6.50 |
The mean daily insulin was based on a 4-week interval prior to week 26 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
| Units/day (U/day) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Mean Daily Insulin Lispro Dose | 16.64 ± 2.76 | 26.16 ± 2.80 | 18.12 ± 3.00 |
Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Percentage of Participants With Estimated Average Glucose <154 mg/dL | 64.9 | 52.5 | 56.4 |
Change from baseline in serum creatinine (sCr) levels after treatment.
| mg/dL | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Serum Creatinine (sCr) | 0.10 (-0.04 to 0.28) | 0.02 (-0.15 to 0.15) | 0.04 (-0.14 to 0.20) |
The change in estimated glomerular filtration rate (eGFR) by using CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation.
| milliliter/minute/1.73m2 (mL/min/1.73m2) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) | -2.5 (-6.0 to 1.0) | -1.0 (-4.5 to 3.0) | -1.0 (-5.5 to 3.0) |
Estimated creatinine clearance (eCrCl) was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.
| milliliter/minute (ml/min) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Estimated Creatinine Clearance (eCrCl) | -2.0 (-4.0 to 0.5) | -1.0 (-3.5 to 2.0) | -0.5 (-4.0 to 2.0) |
The change from baseline in Urinary Albumin to Creatinine Ratio (UACR).
| gram/kilogram (g/kg) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Urinary Albumin to Creatinine Ratio (UACR) | -1.3 (-71.7 to 62.0) | -11.1 (-147.8 to 33.2) | -10.2 (-180.5 to 53.1) |
LS means were calculated from a REML based MMRM model: Change from Baseline = treatment, week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured. •
| kilogram (kg) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Body Weight | 1.11 ± 0.346 | -2.02 ± 0.357 | -2.81 ± 0.374 |
Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Total Hypo | 71.6 | 50.8 | 43.2 |
| Documented Symptomatic Hypo | 60.3 | 40.7 | 31.6 |
| Severe Hypo | 4.1 | 1.1 | 0 |
| Nocturnal Hypo | 38.1 | 15.9 | 13.2 |
Hypoglycemic events (HE) were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
| Events/Participant/Year | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Total HE Rate | 17.07 ± 27.70 | 7.76 ± 20.39 | 5.45 ± 12.54 |
| Documented Symptomatic HE Rate | 11.34 ± 22.04 | 4.86 ± 13.37 | 4.19 ± 11.58 |
| Severe HE Rate | 0.10 ± 0.56 | 0.03 ± 0.31 | 0.00 ± 0.00 |
| Nocturnal HE Rate | 3.06 ± 7.26 | 0.73 ± 2.25 | 0.63 ± 2.26 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means in HbA1c were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, MA region, Baseline CKD Severity, week, treatment\*week, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
| percentage of HbA1c | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in HbA1c | -1.00 ± 0.12 | -1.10 ± 0.12 | -1.10 ± 0.13 |
Percentage of participants whose HbA1c was \<7.0% based on last observation carried forward (LOCF).
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Percentage of Participants Whose HbA1c is <7.0% | 29.1 | 33.5 | 32.9 |
Percentage of participants whose HbA1c was \<8.0% based on last observation carried forward (LOCF).
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Percentage of Participants Whose HbA1c is <8.0% | 70.3 | 69.5 | 69.1 |
The daily mean of 8-point SMPG profile at Week 52 is presented. Participants were required to perform two 8-point SMPG profiles over a 1-week period at 5 separate times throughout the study. LS means were calculated using the MMRM model including the corresponding baseline value as a continuous covariate, as well as baseline HbA1c, MA-region, treatment, week, treatment\*week, baseline CKD severity, and log baseline eGFR (within CKD severity).The two 8-point SMPG profiles were collected on two non-consecutive days (pre-meal and 2-hour postprandial SMPG x \[morning, midday, and evening meals in one day\] + bedtime + 5 hours after bedtime).
| mg/dL | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in 8-Point SMPG | -40.5 ± 3.59 | -30.0 ± 3.75 | -27.2 ± 3.93 |
LS means were calculated using MMRM with the change in FG as the dependent variable and treatment, MA -region, Baseline CKD Severity, week, treatment\*week, baseline FG, baseline HbA1c (%), log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured
| mg/dL | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in FG | -6.4 ± 6.38 | 20.8 ± 6.58 | 28.3 ± 6.87 |
The mean daily insulin was based on a 4-week interval prior to week 52 assessments. LS means were calculated using a REML based mixed-effects model for repeated measures (MMRM) with the change in mean daily insulin as the dependent variable and treatment, MA-region, Baseline HbA1c, baseline mean daily insulin, baseline CKD Severity, week, treatment\*week, log baseline eGFR (within CKD severity), and participant was the random effect. Covariance structure = Unstructured.
| U/day | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change in Mean Daily Insulin Lispro Dose | 16.84 ± 2.87 | 27.46 ± 2.93 | 20.05 ± 3.13 |
Percentage of Participants With Estimated Average Glucose \<154 milligram/deciliter (mg/dL) was based on last observation carried forward (LOCF).
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Percentage of Participants With Estimated Average Glucose <154 mg/dL | 73.7 | 57.4 | 50.9 |
Change from baseline in sCr levels after treatment.
| mg/dL | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in sCr | 0.12 (-0.05 to 0.38) | 0.04 (-0.11 to 0.27) | 0.07 (-0.11 to 0.21) |
The change in eGFR by using CKD-EPI equation.
| mL/min/1.73m2 | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in eGFR | -3.3 (-7.5 to 1.0) | -1.5 (-5.5 to 2.5) | -2.0 (-6.0 to 2.5) |
eCrCl was calculated by Cockcroft-Gault \[Cockcroft and Gault 1976\] equation using baseline estimated lean body weight.
| mL/min | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in eCrCl | -2.5 (-5.8 to 0.5) | -1.3 (-4.0 to 1.5) | -1.5 (-5.0 to 1.5) |
The change from baseline in UACR
| g/kg | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in UACR | 3.5 (-56.2 to 138.1) | -3.0 (-88.5 to 87.6) | -11.5 (-158.0 to 42.9) |
LS means were calculated from a REML based MMRM model: Change from Baseline = treatment , week, treatment\*Week, MA-region, Baseline HbA1c (%), Baseline Body Weight (kg), Baseline CKD Severity, Log Baseline eGFR (within CKD severity), where participant enters the model as a random effect. Covariance structure = Unstructured.
| kg | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Change From Baseline in Body Weight | 1.57 ± 0.429 | -1.71 ± 0.448 | -2.66 ± 0.467 |
Hypoglycemic events (HE) were classified as severe (defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions), documented symptomatic (defined as any time a participant feels that he/she is experiencing symptoms and/or signs associated with hypoglycemia, and has a plasma glucose level of ≤3.9 mmol/L (≤70 mg/dL), nocturnal (defined as any hypoglycemic event that occurs between bedtime and waking). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
| percentage of participants | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Total Hypo | 74.7 | 59.8 | 50.0 |
| Documented Symptomatic Hypo | 63.4 | 48.1 | 40.5 |
| Severe Hypo | 6.7 | 2.6 | 0 |
| Nocturnal Hypo | 47.9 | 23.8 | 20.5 |
HE were classified as total HE rate, documented symptomatic hypoglycemia, severe hypoglycemia, and nocturnal. The 1-year adjusted rate of HEs was summarized cumulatively at 52 weeks. A summary of other nonserious AEs, and all SAEs, regardless of causality, is located in the Reported Adverse Events section.
| Events/Participant/Year | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Total HE Rate | 14.36 ± 22.20 | 7.59 ± 17.81 | 5.82 ± 13.70 |
| Documented Symptomatic HE Rate | 9.62 ± 17.72 | 4.34 ± 9.30 | 4.44 ± 12.23 |
| Severe HE Rate | 0.09 ± 0.37 | 0.03 ± 0.21 | 0.00 ± 0.00 |
| Nocturnal HE Rate | 2.48 ± 5.10 | 0.76 ± 2.09 | 0.70 ± 2.29 |
Participants with Events of Allergic/Hypersensitivity Reactions: Angioedema Standardized MedDRA Query (SMQ), Anaphylactic Reaction SMQ, or Severe Cutaneous Adverse Reactions SMQ
| participants with events | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Angioedema SMQ | 1 | 2 | 2 |
| Angioedema | 0 | 0 | 1 |
| Eyelid edema | 0 | 1 | 0 |
| Face edema | 0 | 1 | 1 |
| Urticaria | 1 | 0 | 0 |
| Anaphylactic Reaction SMQ | 1 | 0 | 0 |
| Circulatory collapse | 1 | 0 | 0 |
| Severe Cutaneous Adverse Reactions SMQ | 0 | 0 | 0 |
Collected over Up To Week 52. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Glargine | — | 56/194 (28.9%) | 130/194 (67%) |
| Dulaglutide 0.75 mg | — | 48/190 (25.3%) | 134/190 (70.5%) |
| Dulaglutide 1.5 mg | — | 41/192 (21.4%) | 144/192 (75%) |
| Event | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 13/194 | 6/190 | 1/192 |
| Acute myocardial infarctionCardiac disorders | 4/194 | 6/190 | 0/192 |
| Acute kidney injuryRenal and urinary disorders | 2/194 | 5/190 | 3/192 |
| PneumoniaInfections and infestations | 3/194 | 3/190 | 0/192 |
| Blood creatinine increasedInvestigations | 2/194 | 3/190 | 3/192 |
| Cardiac failureCardiac disorders | 1/194 | 1/190 | 3/192 |
| Chest painGeneral disorders | 0/194 | 0/190 | 3/192 |
| Angina unstableCardiac disorders | 3/194 | 2/190 | 1/192 |
| CellulitisInfections and infestations | 3/194 | 0/190 | 1/192 |
| Urinary tract infectionInfections and infestations | 3/194 | 2/190 | 1/192 |
| Event | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg |
|---|---|---|---|
| Blood creatinine increasedInvestigations | 90/194 | 71/190 | 74/192 |
| NauseaGastrointestinal disorders | 9/194 | 27/190 | 38/192 |
| DiarrhoeaGastrointestinal disorders | 14/194 | 30/190 | 31/192 |
| VomitingGastrointestinal disorders | 9/194 | 16/190 | 26/192 |
| Glomerular filtration rate decreasedInvestigations | 26/194 | 20/190 | 17/192 |
| Upper respiratory tract infectionInfections and infestations | 20/194 | 13/190 | 8/192 |
| HypertensionVascular disorders | 20/194 | 13/190 | 14/192 |
| Urinary tract infectionInfections and infestations | 19/194 | 10/190 | 13/192 |
| Weight increasedInvestigations | 16/194 | 9/190 | 9/192 |
| InfluenzaInfections and infestations | 10/194 | 15/190 | 12/192 |
All participants who received at least one dose of study drug and had evaluable post-baseline measurements.
| Age, Continuous(years) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| Mean | 64.3 ± 8.41 | 64.7 ± 8.61 | 64.7 ± 8.83 | 64.6 ± 8.60 |
| Sex: Female, Male(Participants) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| Female | 101 | 86 | 88 | 275 |
| Male | 93 | 104 | 104 | 301 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 79 | 75 | 78 | 232 |
| Not Hispanic or Latino | 115 | 115 | 114 | 344 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 18 | 17 | 12 | 47 |
| Asian | 5 | 4 | 7 | 16 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 26 | 36 | 26 | 88 |
| White | 137 | 122 | 134 | 393 |
| More than one race | 6 | 7 | 10 | 23 |
| Unknown or Not Reported | 1 | 4 | 3 | 8 |
| Region of Enrollment(Participants) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| Romania | 14 | 9 | 14 | 37 |
| Hungary | 22 | 19 | 14 | 55 |
| United States | 61 | 59 | 62 | 182 |
| Ukraine | 17 | 11 | 12 | 40 |
| Brazil | 44 | 47 | 50 | 141 |
| Poland | 1 | 2 | 2 | 5 |
| Mexico | 19 | 19 | 15 | 53 |
| South Africa | 14 | 20 | 17 | 51 |
| Spain | 2 | 4 | 6 | 12 |
| Body Weight(kilogram (kg)) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| Mean | 88.20 ± 18.488 | 90.88 ± 18.301 | 88.14 ± 16.015 | 89.06 ± 17.653 |
| Body Mass Index (BMI)(kilogram/square meter (kg/m^2)) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| Mean | 32.39 ± 5.324 | 33.00 ± 5.546 | 32.11 ± 4.841 | 32.50 ± 5.248 |
| Hemoglobin A1C (HbA1c) at Baseline(Percentage of HbA1c) | Insulin Glargine | Dulaglutide 0.75 mg | Dulaglutide 1.5 mg | Total |
|---|---|---|---|---|
| Mean | 8.56 ± 0.966 | 8.57 ± 1.088 | 8.59 ± 0.860 | 8.57 ± 0.973 |
3 further baseline measures are reported on the registry.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Jul 2012, a primary completion of Jun 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide